EE9 A Cost-Effectiveness Analysis of Abrocitinib vs. Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.395
https://www.valueinhealthjournal.com/article/S1098-3015(25)02952-3/fulltext
Title :
EE9 A Cost-Effectiveness Analysis of Abrocitinib vs. Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02952-3&doi=10.1016/j.jval.2025.09.395
First page :
Section Title :
Open access? :
No
Section Order :
12701